- First name: Thomas
- Surname: Taapken
- Position: Ph.D., Chairman of the Board
Thomas Taapken joined Imcyse as Chairman of the Board in 2019 steering the Company’s transition period after its Series B financing and successful reorganization of the management team. Thomas has over 25 years of experience in senior management positions within the life sciences sector and as a venture investor. Thomas has been CFO of lnflaRx since 2020 and has previously held positions as CFO of Medigene AG (publicly listed in Germany), as CEO and CFO of Epigenomics AG (publicly listed in Germany), where he led the company's efforts in gaining regulatory approval for the company's lead product with the FDA and oversaw its subsequent introduction into the US market, and as CFO at Biotie Therapies (Turku, Finland) and its predecessor companies. Before that he was a venture investor for 7 years with Deutsche Venture Capital (DVC) and Burrill & Co. in the US. Thomas started his career at Hoechst AG (now Sanofi). He holds a Ph.D. in organic chemistry from the Technical University of Berlin and also studied economics, chemistry and physics at the University of Göttingen. Thomas is a Board member of Scibase AB since 2017 and Board member at Memo Therapeutics AG since 2021.
- Hits: 171